SCHEDULE: FMR LLC Reports 6.8% Stake in Dyne Therapeutics

FMR LLC and Abigail P. Johnson have reported beneficial ownership of 6.8% of Dyne Therapeutics Inc.'s common stock as of June 30, 2026.

Summary

• FMR LLC and Abigail P. Johnson have filed a Schedule 13G, indicating their beneficial ownership of Dyne Therapeutics Inc. common stock.
• As of June 30, 2026, the aggregate amount beneficially owned is 11,206,999.89 shares.
• This represents 6.8% of the class of securities.
• FMR LLC is classified as a holding company (HC), and Abigail P. Johnson is classified as an insider (IN) in relation to the filing.
• The filing confirms that no single other person's interest in the common stock exceeds five percent.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting a change in beneficial ownership without new operational or financial disclosures.

Positives

• Significant institutional ownership by FMR LLC and Abigail P. Johnson, suggesting confidence in the company's long-term prospects.
• Clear reporting of beneficial ownership, adhering to regulatory requirements.

Negatives

• The filing does not contain new operational or financial performance data, limiting insights into the company's current health.

Risks

• The filing itself does not introduce new risks, but the underlying investment in Dyne Therapeutics Inc. carries inherent risks associated with the biotechnology sector.

Future Outlook

This filing is a report of beneficial ownership and does not contain forward-looking statements or guidance regarding Dyne Therapeutics Inc.'s future performance.

Management Comments

• FMR LLC and Abigail P. Johnson may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC.
• This filing reflects securities beneficially owned by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the 'FMR Reporters').

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for large institutional investors like FMR LLC when they acquire a significant stake (typically 5% or more) in a publicly traded company. This filing indicates FMR LLC's investment activity in the biotechnology sector, specifically in Dyne Therapeutics Inc.

Corporate Governance

Stakeholder Impact

• Shareholders: The filing confirms significant institutional interest, which can be viewed positively, but it does not provide new information about the company's performance.
• Management: The filing does not directly impact management but reflects their fiduciary duty in managing assets.
• Regulators: Ensures compliance with SEC disclosure requirements regarding beneficial ownership.

Next Steps

• FMR LLC and Abigail P. Johnson will continue to hold their beneficial ownership in Dyne Therapeutics Inc.
• Future filings will be made if there are material changes in beneficial ownership.

Key Dates

Keywords

Dyne Therapeutics, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor